Updates in the treatment of cardiomyopathies in children

Pediatric cardiomyopathy is a rare but potentially life-threatening group of myocardial disorders characterized by structural and functional abnormalities of the heart muscle. Although the incidence is estimated at ۱-۲ per ۱۰۰,۰۰۰ children, it represents a major cause of heart failure, arrhythmias, and sudden cardiac death in this age group. Pediatric cardiomyopathy is classified into dilated, hypertrophic, restrictive, arrhythmogenic, and unclassified subtypes. Genetic mutations, metabolic disorders, and infections are among the most frequent etiologies. Early recognition through echocardiography, cardiac MRI, and genetic testing is critical. Management includes pharmacological therapy, device implantation, and, in severe cases, heart transplantation. Novel approaches such as gene-targeted therapy and regenerative medicine are under investigation. Prognosis remains highly variable depending on etiology, age at presentation, and response to treatment.

کلیدواژه ها:

cardiomyopathies ، children ، Novel approaches